MedTrace Logo

Older Breast Cancer Patients: Risk for Cognitive Decline

NCT03451383 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1700

Last updated 2025-03-11

No results posted yet for this study

Summary

The goal of this study is to evaluate the impact of systemic therapy on cognition in older breast cancer patients, explore change in APE, LM and Cognition domains, measure associations between cognitive decline and QOL, and describe how genetic polymorphisms, inflammatory biomarkers, sleep and physical measures moderate cognitive outcomes. This study is being done nationally, with recruiting sites at Georgetown University, Montgomery General Hospital, Virginia Cancer Specialists, Washington Hospital Center, Reston Breast Care Specialists, Memorial Sloan-Kettering, Moffitt Cancer Center, City of Hope National Medical Center, Hackensack University Medical Center, Indiana University and University of California, Los Angeles.

Conditions

Sponsors & Collaborators

  • Memorial Sloan Kettering Cancer Center

    collaborator OTHER

  • Indiana University

    collaborator OTHER

  • H. Lee Moffitt Cancer Center and Research Institute

    collaborator OTHER

  • City of Hope Medical Center

    collaborator OTHER

  • Hackensack Meridian Health

    collaborator OTHER

  • Georgetown University

    lead OTHER

Principal Investigators

  • Jeanne Mandelblatt · Lombardi Comprehensive Cancer Center

Eligibility

Min Age
60 Years
Max Age
105 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-01
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03451383 on ClinicalTrials.gov